Latest Conference Articles

November 17th 2017, 9:34pm

EMUC Congress

Andrea Necchi, MD, a medical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, discusses the impact of PD-1 inhibition in bladder cancer as well as the promise with combination strategies.

November 16th 2017, 1:34am

PER® Chemotherapy Foundation Symposium (CFS)

Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses endpoints in clinical trials for ovarian cancer.

November 15th 2017, 10:13pm

PER® Chemotherapy Foundation Symposium (CFS)

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

November 11th 2017, 2:47am

PER® Chemotherapy Foundation Symposium (CFS)

Christopher Sweeney, MBBS, physician, Dana-Farber Cancer Institute, compares treatment with abiraterone verus docetaxel in patients with prostate cancer.

November 11th 2017, 2:46am

PER® Chemotherapy Foundation Symposium (CFS)

It has been a “renaissance” in the non–small cell lung cancer landscape with the rapid evolution of targeted treatment for patients with EGFR-mutation–positive disease, says Edward S. Kim, MD.

November 11th 2017, 2:15am

PER® Chemotherapy Foundation Symposium (CFS)

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

November 11th 2017, 12:14am

PER® Chemotherapy Foundation Symposium (CFS)

The approach to first-line treatment of advanced non-small cell lung cancer (NSCLC) has been evolving rapidly, particularly with respect to patients with lung adenocarcinoma.

November 10th 2017, 11:15pm

PER® Chemotherapy Foundation Symposium (CFS)

Immunotherapy is being positioned as an earlier therapeutic option for patients with high levels of microsatellite instability or mismatch repair deficiency, regardless of their tumor location, expert says.

November 10th 2017, 2:47am

SITC Meeting

A variety of adoptive T-cell therapy strategies have shown promise in clinical studies with recent FDA approvals granted to CAR-modified T-cell therapies, representing the potential for future combination strategies.

November 10th 2017, 1:44am

PER® Chemotherapy Foundation Symposium (CFS)

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the significant advances with CDK4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.

November 10th 2017, 12:44am

PER® Chemotherapy Foundation Symposium (CFS)

PARP inhibitors offer exciting opportunities to improve outcomes for patients with ovarian cancer and hopefully will be moved to the front-line setting if the evidence warrants it, said Susana M. Campos, MD.

November 10th 2017, 12:18am

PER® Chemotherapy Foundation Symposium (CFS)

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ongoing roles of regorafenib (Stivarga) and TAS-102 (Lonsurf) in colorectal cancer (CRC) treatment.

November 9th 2017, 11:06pm

PER® Chemotherapy Foundation Symposium (CFS)

There is a great need—and opportunity—to improve ovarian cancer outcomes by understanding the immune milieu of ovarian cancers and harnessing the power of immunotherapy.

November 9th 2017, 10:58pm

PER® Chemotherapy Foundation Symposium (CFS)

The tumor-site agnostic FDA approval of the PD-1 inhibitor pembrolizumab (Keytruda) for patients with microsatellite instability-high or mismatch repair deficient solid tumors has helped propel endometrial cancer into the immunotherapy age.

November 9th 2017, 7:00pm

ESGO Congress

Umesh Mahantshetty, MD, shares his insight on the state of cervical cancer treatment in developing countries.

November 9th 2017, 2:47am

PER® Chemotherapy Foundation Symposium (CFS)

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ongoing role and impact of regorafenib (Stivarga) in the paradigm of hepatocellular carcinoma (HCC) in an interview during the 2017 Chemotherapy Foundation Symposium.

November 9th 2017, 2:34am

PER® Chemotherapy Foundation Symposium (CFS)

As clinicians’ understanding of the disease pathobiology associated with Hodgkin lymphoma (HL) has increased, novel treatments have emerged.

November 9th 2017, 1:48am

PER® Chemotherapy Foundation Symposium (CFS)

Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses updates to the treatment paradigm of high-risk multiple myeloma in an interview during the 2017 Chemotherapy Foundation Symposium.

November 9th 2017, 1:33am

PER® Chemotherapy Foundation Symposium (CFS)

The next frontier in advancing the field of chronic lymphocytic leukemia (CLL) is identifying patients who will not experience long-term progression-free survival on novel agents.

November 9th 2017, 1:32am

PER® Chemotherapy Foundation Symposium (CFS)

Because genetic abnormalities play a role in multiple myeloma, it is important to understand these better to improve outcomes, particularly for high-risk patients, said Shaji K. Kumar, MD.